{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:43:08Z","timestamp":1780580588156,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1038\/s41366-020-0544-4","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T12:02:47Z","timestamp":1583755367000},"page":"1021-1027","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The cardiovascular safety of antiobesity drugs\u2014analysis of signals in the FDA Adverse Event Report System Database"],"prefix":"10.1038","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0193-6858","authenticated-orcid":false,"given":"Einat","family":"Gorelik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Gorelik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Masarwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amichai","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruria","family":"Hirsh-Raccah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Matok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"key":"544_CR1","unstructured":"World Health Organization. Overweight and obesity. 2017. http:\/\/www.who.int\/gho\/ncd\/risk_factors\/overweight_obesity\/obesity_adults\/en\/. Accessed 29 May 2018."},{"key":"544_CR2","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1345\/aph.1R779","volume":"47","author":"JW Fleming","year":"2013","unstructured":"Fleming JW, McClendon KS, Riche DM. New obesity agents: lorcaserin and phentermine\/topiramate. Ann Pharmacother. 2013;47:1007\u201316.","journal-title":"Ann Pharmacother."},{"key":"544_CR3","unstructured":"Centers for Disease Control and Prevention. Adult obesity facts. 2018. https:\/\/www.cdc.gov\/obesity\/data\/adult.html. Accessed 14 Sep 2018."},{"key":"544_CR4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/dom.12657","volume":"18","author":"AJ Krentz","year":"2016","unstructured":"Krentz AJ, Fujioka K, Hompesch M. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. Diabetes Obes Metab. 2016;18:558\u201370.","journal-title":"Diabetes Obes Metab"},{"key":"544_CR5","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1016\/S0140-6736(14)61748-7","volume":"385","author":"WH Dietz","year":"2015","unstructured":"Dietz WH, Baur LA, Hall K, Puhl RM, Taveras EM, Uauy R, et al. Management of obesity: improvement of health-care training and systems for prevention and care. Lancet. 2015;385:2521\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(14)61748-7.","journal-title":"Lancet"},{"key":"544_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-016-0735-y","volume":"14","author":"IJ Onakpoya","year":"2016","unstructured":"Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. BMC Med. 2016;14:1\u201311. https:\/\/doi.org\/10.1186\/s12916-016-0735-y.","journal-title":"BMC Med"},{"key":"544_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1161\/CIRCULATIONAHA.105.593459","volume":"113","author":"RJ Levy","year":"2006","unstructured":"Levy RJ. Serotonin transporter mechanisms and cardiac disease. Circulation. 2006;113:2\u20134.","journal-title":"Circulation."},{"key":"544_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM199809103391102","volume":"339","author":"Hershel Jick","year":"1998","unstructured":"Jick Hershel, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 1998;339:719\u201324.","journal-title":"N Engl J Med"},{"key":"544_CR9","doi-asserted-by":"crossref","unstructured":"Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000;102:2836\u201341. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11104741.","DOI":"10.1161\/01.CIR.102.23.2836"},{"key":"544_CR10","doi-asserted-by":"crossref","unstructured":"Michelakis Evangelos D, Weir EK. Anorectic drugs and pulmonary hypertension from the bedside to the bench. Am J Med Sci. 2001;321:292\u20139. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0002962915346772?via%3Dihub.","DOI":"10.1097\/00000441-200104000-00009"},{"key":"544_CR11","doi-asserted-by":"crossref","unstructured":"Watts SW, Davis RP. 5-Hydroxtryptamine receptors in systemic hypertension: an arterial focus. Cardiovasc Ther. 2012;29:54\u201367. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2943543\/pdf\/nihms209317.pdf.","DOI":"10.1111\/j.1755-5922.2010.00173.x"},{"key":"544_CR12","unstructured":"U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA recommends against the continued use of Meridia (sibutramine). U.S. Food and Drug Administration; 2010. FDA announcement available at https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fdarecommends-against-continued-use-meridia-sibutramine. Accessed 16 Feb 2020."},{"key":"544_CR13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMoa1003114","volume":"363","author":"WPT James","year":"2010","unstructured":"James WPT, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP. et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1003114.","journal-title":"N Engl J Med"},{"key":"544_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1463-1326.2011.01554.x.","volume":"14","author":"ID Caterson","year":"2012","unstructured":"Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab. 2012;14:523\u201330. https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01554.x.","journal-title":"Diabetes Obes Metab"},{"key":"544_CR15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/ijcp.12771","volume":"70","author":"D Haslam","year":"2016","unstructured":"Haslam D. Weight management in obesity\u2014past and present. Int J Clin Pract. 2016;70:206\u201317.","journal-title":"Int J Clin Pract"},{"key":"544_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/00325481.2018.1435129","volume":"130","author":"DK Patel","year":"2018","unstructured":"Patel DK, Stanford FC. Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med. 2018;130:173\u201382. https:\/\/doi.org\/10.1080\/00325481.2018.1435129.","journal-title":"Postgrad Med"},{"key":"544_CR17","unstructured":"U.S. Food and Drug Administration (FDA). Questions and answers on FDA\u2019s Adverse Event Reporting System (FAERS). U.S. Food and Drug Administration; 2018. FDA information site https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers. Accessed 16 Feb 2020."},{"key":"544_CR18","doi-asserted-by":"crossref","unstructured":"Yoshimura K, Kadoyama K, Sakaeda T, Sugino Y, Ogawa O. A survey of the FAERS database concerning the adverse event profiles of \u03b1 1-adrenoreceptor blockers for lower urinary tract symptoms. 2013;10.","DOI":"10.7150\/ijms.5892"},{"key":"544_CR19","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10:796\u2013803.","journal-title":"Int J Med Sci"},{"key":"544_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/00325481.2018.1435129","volume":"130","author":"DK Patel","year":"2018","unstructured":"Patel DK, Stanford FC. Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med. 2018;130:173\u201382.","journal-title":"Postgrad Med."},{"key":"544_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"544_CR22","doi-asserted-by":"crossref","unstructured":"Mckinney W. Data structures for statistical computing in Python. Proceedings of the 9th Python in Science Conference. 2010;16979000(Scipy):51\u20136.","DOI":"10.25080\/Majora-92bf1922-00a"},{"key":"544_CR23","doi-asserted-by":"crossref","unstructured":"Seabold S, Perktold J. Statsmodels: econometric and statistical modeling with Python. Proceedings of the 9th Python in Science Conference. 2010;(Scipy):57\u201361.","DOI":"10.25080\/Majora-92bf1922-011"},{"key":"544_CR24","unstructured":"DrugBank. Lorcaserin. 2018. https:\/\/www.drugbank.ca\/drugs\/DB04871. Accessed 29 May 2018."},{"key":"544_CR25","doi-asserted-by":"publisher","unstructured":"Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, et al. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med. 2018. https:\/\/doi.org\/10.1056\/NEJMoa1808721.","DOI":"10.1056\/NEJMoa1808721"},{"key":"544_CR26","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu FMN. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30:891\u20138.","journal-title":"Drug Saf"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41366-020-0544-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41366-020-0544-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41366-020-0544-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:17:39Z","timestamp":1684617459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-020-0544-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["544"],"URL":"https:\/\/doi.org\/10.1038\/s41366-020-0544-4","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,9]]},"assertion":[{"value":"5 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}